Scalper1 News
Regeneron Pharmaceuticals (REGN) plunged 10% Friday afternoon after trading was briefly halted for volatility, after word got out that the FDA is investigating its cholesterol-drug candidate for adverse effects. The item was buried deep in a 20-F form Regeneron’s big-pharma partner Sanofi (SNY) filed Friday. Under a discussion of the two firms’ collaboration on alirocumab, a monoclonal antibody of a type called PCSK9 for treating high cholesterol, Scalper1 News
Scalper1 News